In pressurised metered-dose inhalation, salbutamol sulfate is processed as a micronized suspension rather than a dissolved component because the salt's solubility in hydrofluoroalkane propellants is below the threshold that would allow a single-phase formulation at the required dose. The label claim of 100 µg salbutamol per actuation is expressed as salbutamol base, while the input raw material is salbutamol sulfate with a salt-to-base correction factor of 1.204; therefore, each actuation must deliver 120.5 µg salbutamol sulfate. For a metering valve chamber of 63 µL, the suspension concentration is calculated as 1.91 mg/mL at 20 °C. For a 200-actuation canister, the total salbutamol sulfate input is 24.1 mg, with loss allowance established during process qualification and not applied to reduce label claim. The finished product is controlled under Ph. Eur. 2.9.18 and USP <601> for aerodynamic particle size distribution and delivered dose uniformity, while the canister closure system is qualified under 21 CFR 211.94; residual ethanol and elemental impurities are managed under ICH Q3C and ICH Q3D. Downstream manufacture begins with air-jet milling of the sulfate in a spiral jet mill with integral classifier using dry nitrogen to a target laser diffraction particle size of Dv90 ≤ 5.0 µm and Dv50 1.8–2.5 µm measured according to ISO 13320:2020. The micronized API is conditioned in a vacuum dryer at <40% RH before dispersion into pre-chilled HFA-134a or HFA-227ea vehicle in a jacketed vessel at 2–8 °C using a low-shear impeller. High-shear homogenisation is avoided because it can increase amorphous surface content and induce crystal growth on valve stem seats. The suspension is pressure-filled through a non-aqueous fill line into aluminium canisters at 10–14 bar backpressure, followed immediately by valve crimping and heated-bath leak testing. Aerodynamic size distribution is determined by cascade impactor using a Next Generation Impactor calibrated to the registered actuator geometry; the pressure filling head is the rate-limiting station because the suspension must be kept under gentle recirculation to avoid sedimentation. Terminal products are 100 µg per actuation pMDI devices with 200 actuations, using a metered-dose canister and a plastic actuator whose orifice diameter and spray angle are selected from the registered actuator design to match the suspension flocculation state. Published head-to-head data for different HFA blends at this exact fill concentration is limited; therefore, process qualification runs under the registered valve and canister configuration are required to establish suspension homogeneity before release.

Does Micronized Salbutamol Sulfate Need Carrier Redesign in Capsule-Based Dry Powder Inhalation?

In dry powder inhalation, salbutamol sulfate is filled into hard capsules as a low-dose blend with lactose monohydrate carrier particles, but the same micronized API used in pMDI cannot be transferred to a DPI blend without re-evaluating interparticulate forces. For a 200 µg salbutamol base dose, 240.6 µg salbutamol sulfate is required per capsule; a 25 mg fill weight therefore gives 0.96% w/w active loading, while a 12.5 mg fill gives 1.92% w/w. The carrier is a milled α-lactose monohydrate with fine-particle fraction between 5% w/w and 15% w/w, carrier particle size Dv50 50–70 µm and Dv90 <100 µm, because this range balances powder flow and API detachment without excessive throat deposition. Aerodynamic performance is tested according to Ph. Eur. 2.9.18 and USP <601>; content uniformity is assessed by USP <905>, and residual moisture in the lactose carrier is controlled below 1.0% w/w. Downstream blending uses a low-shear tumble blender at 6–12 rpm for 20–40 min with vessel fill volume limited to 15–25% of total capacity; high-shear mixing is avoided because it promotes triboelectric charging and lactose carrier attrition, both of which alter fine particle fraction retention on cascade impaction. The final blend is sampled at 10 separate positions and accepted only if assay relative standard deviation is ≤ 3.0%. Capsule filling on a dosator or tamping-pin machine is conducted at 30–40% RH and 20–25 °C, because moisture uptake above 45% RH increases powder cohesion, reduces capsule fill weight consistency, and depresses fine particle fraction. Filled capsules undergo weight sorting and foreign-particle inspection. Terminal presentations are single-dose DPI capsules in PVC/aluminium blisters, administered through passive or breath-actuated inhaler devices.

Nebulised salbutamol sulfate solution manufacture differs from pMDI processing because the API is fully dissolved in aqueous medium and must remain chemically stable through terminal sterilisation or aseptic fill. A 2.5 mL unit-dose ampoule labelled 2.5 mg salbutamol base contains 3.01 mg salbutamol sulfate, corresponding to 1.204 mg/mL sulfate; a 5 mg base ampoule of 2.5 mL requires 6.02 mg sulfate. The product is controlled under ISO 27427:2013 for nebulising system compatibility, Ph. Eur. 2.6.1 for sterility, Ph. Eur. 2.6.14 for bacterial endotoxins, Ph. Eur. 2.9.19 for particulate matter, and USP <85> for endotoxin; container closure integrity is evaluated according to USP <1207>. Downstream manufacture starts with dissolution in Water for Injections at 25 ± 5 °C; sodium chloride is added at 0.9% w/v for isotonicity, and pH is adjusted to 3.5–4.5 with dilute sulfuric acid because salbutamol sulfate oxidation is accelerated in alkaline solution. Dissolved oxygen in the finished solution is controlled below 2.0 mg/L by nitrogen sparging before and during filtration through a 0.22 µm polyethersulfone membrane. The solution is either filled aseptically or steam-sterilised at 121 °C for 15 min if the container-closure system is validated for terminal sterilisation. Blow-fill-seal lines and conventional form-fill-seal lines are both used, with extrusion temperature and mould cooling time controlled to container weight and wall thickness. Terminal products are low-density polyethylene unit-dose ampoules of 2.5 mg/2.5 mL and 5 mg/2.5 mL base equivalents, used with jet or mesh nebulisers.

Oral Tablet Granulation and Compression Window for Salbutamol Sulfate

Compressed low-dose salbutamol sulfate units are manufactured with direct compression or dry granulation rather than aqueous wet granulation because the water-soluble salt can migrate to granule surfaces during drying, producing content non-uniformity at the 2 mg base dose. A tablet labelled 2 mg salbutamol base contains 2.4 mg salbutamol sulfate; in a 120 mg core this corresponds to 2.0% w/w active loading, and in a 200 mg core to 1.2% w/w. Release testing follows the compendial Salbutamol Sulfate Tablets monograph and USP <905> for uniformity of dosage units; residual solvents are monitored under ICH Q3C, elemental impurities under ICH Q3D, and stability under 21 CFR 211.166. The production sequence begins with geometric pre-blending of salbutamol sulfate with 1 part API to 5–10 parts lactose monohydrate in a bin blender at 6–12 rpm for 20–40 min, followed by addition of microcrystalline cellulose and final blending with magnesium stearate. Pre-drying of excipients at 45–50 °C is required when ambient relative humidity exceeds 55% RH because moisture-activated cohesion reduces blend flow and increases weight variation. Blend uniformity is sampled at 10 points and accepted only if assay relative standard deviation is ≤ 5.0%. Compression on a rotary press uses precompression 4–8 kN and main compression 8–15 kN, with tablet hardness, friability, and disintegration monitored as in-process controls; friability is maintained below 1.0%. Terminal presentations are oral tablets of 2 mg and 4 mg base equivalents, capsules, and oral granules where regional marketing authorisations permit.

When Salbutamol Sulfate Is Formulated as an Oral Liquid, pH Control Governs Solubility and Preservative Activity

In oral syrup manufacture, salbutamol sulfate is dissolved in purified water before addition of bulk sweeteners and buffer salts, because the aqueous solubility of the sulfate allows a true solution at the 0.5 mg/mL base level. For a 2 mg/5 mL base oral syrup, 2.41 mg sulfate per 5 mL is used, equal to 0.482 mg/mL sulfate; batch overage is limited to 100.0% ± 2.0% of label claim. Compliance is anchored to 21 CFR 211.110(a) for in-process controls, ICH Q3C for residual solvents, ICH Q3D for elemental impurities, and USP <1151> for pharmaceutical dosage form quality. The manufacturing sequence begins with dissolution of the sulfate in a portion of purified water at 25 ± 5 °C, followed by addition of citric acid/sodium citrate buffer to maintain pH 3.5–4.5, because at higher pH the active becomes more susceptible to oxidation and at lower pH the sweetener and buffer system may precipitate. Sorbitol, glycerin, and preservative such as sodium benzoate at 0.1–0.2% w/v are added, the batch is made to final volume, filtered through a 20 µm clarifier, and filled into amber PET or glass bottles with child-resistant closures. Mixing uniformity is verified during processing by assay sampling at 5 defined vessel positions, and preservative efficacy is tested by the compendial method with log reduction criteria met at day 14 and day 28. Terminal products are multidose oral syrup 2 mg/5 mL and sugar-free oral solution in 60–150 mL containers.

Injectable presentations of salbutamol sulfate are manufactured under nitrogen-flushed conditions because the active is oxidisable in dilute aqueous solution, particularly at pH above 5.0. When a 0.5 mg/mL base concentration is specified, 0.602 mg/mL salbutamol sulfate is dissolved; a 5 mL ampoule therefore contains 3.01 mg sulfate. The injection is controlled under the relevant pharmacopoeial Salbutamol Injection monograph, Ph. Eur. 2.6.1 for sterility, Ph. Eur. 2.6.14 for bacterial endotoxins, Ph. Eur. 2.9.19 for particulate matter, USP <1> for injectable dosage forms, and USP <85> for endotoxin. Glass container quality and delamination risk are evaluated under USP <660>. Manufacturing begins with Water for Injections sparged with nitrogen to reduce dissolved oxygen, followed by addition of salbutamol sulfate and tonicity agent if required; pH is adjusted to 3.5–4.5 with dilute sulfuric acid. The solution is filtered through 0.22 µm sterilising-grade membrane and filled into Type I glass ampoules under nitrogen, then terminally sterilised at 121 °C for 15 min or processed by validated aseptic filling where the container-closure system cannot withstand terminal sterilisation. Headspace oxygen is maintained below 2.0% v/v by nitrogen flushing and monitored by non-destructive headspace analysis. Terminal products are single-use ampoules labelled in salbutamol base equivalents, intended for intravenous infusion after dilution or slow intravenous injection under hospital supervision.